[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369083-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369083-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","zsh-2208-a-novel-retinoid-with-potent-anti-tumour-effects-on-escc-stem-cells-via-rartnfaip3-axis","ZSH-2208 - A novel retinoid with potent anti-tumour effects on ESCC stem cells via RARγ–TNFAIP3 axis","","Oesophageal squamous cell carcinoma (ESCC) is a globally prevalent malignancy, and cancer stem cells contribute to progression through strong self-renewal and tumourigenic capacity, driving recurrence and drug resistance. ZSH-2208 was developed as a novel retinoid analogue targeting retinoic acid receptors (RARs) to achieve enhanced potency, broader efficacy and minimized toxic side effects against ESCC tumour-repopulating cells (TRCs). Mechanistic studies show ZSH-2208 inhibits ESCC-TRC growth by modulating the RARγ–TNFAIP3 axis, and the clinical relevance of TNFAIP3 in ESCC is supported.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/zsh-2208-a-novel-retinoid-with-potent-anti-tumour-effects-on-escc-stem-cells-via-rartnfaip3-axis/369083/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/zsh-2208-a-novel-retinoid-with-potent-anti-tumour-effects-on-escc-stem-cells-via-rartnfaip3-axis/369083.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is ZSH-2208 and what does it target in ESCC?","Question",{"text":63,"@type":64},"ZSH-2208 is a novel retinoid that targets ESCC tumour-repopulating cells (TRCs) and modulates retinoic acid receptor signaling.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does ZSH-2208 inhibit ESCC-TRC growth?",{"text":68,"@type":64},"ZSH-2208 inhibits ESCC-TRC growth through the RARγ–TNFAIP3 axis, demonstrated by in vivo and in vitro experiments.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is TNFAIP3 important in ESCC, according to the document?",{"text":72,"@type":64},"The document links low TNFAIP3 protein levels with improved survival probability in ESCC patients, supporting clinical significance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369083,1790215607,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","DOI: 10.1002/ctm2.70148  \nRESEARCH ARTICLE  \nZSH-2208: A novel retinoid with potent anti-tumour effects on ESCC stem cells via RARγ–TNFAIP3 axis  \nRuoxue Chen1  Xuan Huang1  Jiayun Hou1  Junjie Ni1  Wenrui Zhao1  Quanlin Li2, 3  Heng Jiao4  Xin Cao1   \n1 Institute of Clinical Science, Zhongshan Hospital, Fudan University Shanghai Medical College, Shanghai, China  \n2 Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China  \n3 Shanghai Collaborative Innovation Center of Endoscopy, Shanghai, China  \n4 Department of Thoracic Surgery, Zhongshan Hospital, Fudan University Shanghai Medical College, Shanghai, China  \nCorrespondence  \nXin Cao, Institute of Clinical Science, Zhongshan Hospital, Fudan University Shanghai Medical College, Shanghai, China.  \n[Email:](Email: caox@fudan.edu.cn)[ caox@fudan.edu.cn](Email: caox@fudan.edu.cn)  \nHeng Jiao, Department of Thoracic Surgery, Zhongshan Hospital, Fudan University Shanghai Medical College, Shanghai, China. [Email:](Email: jiao.heng@zs-hospital.sh.cn)[ jiao.heng@zs-hospital.sh.cn](Email: jiao.heng@zs-hospital.sh.cn)  \nQuanlin Li, Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China.  \nEmail: [li.quanlin@zs-hospital.sh.cn](li.quanlin@zs-hospital.sh.cn)  \nGraphical Abstract  \n∙ The ESCC-TRCs replicates the characteristics of ESCC stem cells, which are inhibited by ZSH-2208 .  \n∙ In vivo and in vitro experiments demonstrated that ZSH-2208, a novel RA analogue, effectively inhibits the growth of ESCC-TRCs through the RARγ–TNFAIP3 axis.  \n∙ Low levels of TNFIP3 protein may be associated with improved survival probability in ESCC patients.  \nClin. Transl. Med. 2025;15:e70148 .  \n[https://doi.org/10.1002/ctm2.70148](https://doi.org/10.1002/ctm2.70148)  \n[wileyonlinelibrary.com/journal/ctm2](wileyonlinelibrary.com/journal/ctm2)  \nDOI: 10.1002/ctm2.70148  \nRESEARCH ARTICLE  \nZSH-2208: A novel retinoid with potent anti-tumour effects on ESCC stem cells via RARγ–TNFAIP3 axis  \nRuoxue Chen1  Xuan Huang1  Jiayun Hou1  Junjie Ni1  Wenrui Zhao1  Quanlin Li2, 3  Heng Jiao4  Xin Cao1   \n1 Institute of Clinical Science, Zhongshan Hospital, Fudan University Shanghai Medical College, Shanghai, China  \n2 Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China  \n3 Shanghai Collaborative Innovation Center of Endoscopy, Shanghai, China  \n4 Department of Thoracic Surgery, Zhongshan Hospital, Fudan University Shanghai Medical College, Shanghai, China  \nCorrespondence  \nXin Cao, Institute of Clinical Science, Zhongshan Hospital, Fudan University Shanghai Medical College, Shanghai, China.  \nEmail: [caox@fudan.edu.cn](caox@fudan.edu.cn)  \nHeng Jiao, Department of Thoracic Surgery, Zhongshan Hospital, Fudan University Shanghai Medical College, Shanghai, China. [Email:](Email: jiao.heng@zs-hospital.sh.cn)[ jiao.heng@zs-hospital.sh.cn](Email: jiao.heng@zs-hospital.sh.cn)  \nQuanlin Li, Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China.  \nEmail: [li.quanlin@zs-hospital.sh.cn](li.quanlin@zs-hospital.sh.cn)  \nFunding information  \nNational Natural Science Foundation of China, Grant/Award Numbers: 82173662, 82373719; National Key R&D Program of China, Grant/Award Numbers: 2023YFC3605702, 2023YFC2308002, 2024YFC3044700; Extraordinary 2025 Elite Project ofFudan University  \nAbstract  \nBackgroud: Oesophageal cancer ranks among the most prevalent malignant tumours globally, primarily consisting of oesophageal squamous cell carcinoma (ESCC) . Cancer stem cells (CSCs) accelerate the progression ESCC via their strong self-renewal and tumourigenic capabilities, presenting significant clinical challenges due to increased risks of recurrence and drug resistance.  \nMethods: Our previous study has reportedWYC-209, which is capable of inducing apoptosis of CSCs in melanoma and hepatoma, but is ineffective against ESCC. Additionally, c","cbCair6M5cniXChR","https://ap.wps.com/l/cbCair6M5cniXChR","pdf",7995226,17,"English","# Key points\n# Graphical abstract\n## Mechanistic findings\n# Abstract\n# Keywords","[{\"question\":\"What is ZSH-2208 and what does it target in ESCC?\",\"answer\":\"ZSH-2208 is a novel retinoid that targets ESCC tumour-repopulating cells (TRCs) and modulates retinoic acid receptor signaling.\"},{\"question\":\"How does ZSH-2208 inhibit ESCC-TRC growth?\",\"answer\":\"ZSH-2208 inhibits ESCC-TRC growth through the RARγ–TNFAIP3 axis, demonstrated by in vivo and in vitro experiments.\"},{\"question\":\"Why is TNFAIP3 important in ESCC, according to the document?\",\"answer\":\"The document links low TNFAIP3 protein levels with improved survival probability in ESCC patients, supporting clinical significance.\"}]","ZSH-2208 - A novel retinoid with potent anti-tumour effects on ESCC stem cells via RARγ–TNFAIP3 axis | PDF",1790180618,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f2a4f4f6c90ea8f245d0573fdf34de1.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d018841802ba1502e19dd1959eeb1341.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86286e0dc2b41a38268f8b7809d4db37.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b79c9db86afd5542a6c66b0f87f926b.webp",980,1287]